Consistently, treatment with gefitinib or cabozantinib markedly reduced PD-L1 expression in HCC827 cells with DUSP22 deletion, linking PD-L1 upregulation to increased cell migration in DUSP22-deleted lung cancer cells. The gene discussed is CD274; the disease is lung cancer.